Perspectives and challenges of interferon-free therapy for chronic hepatitis C
- Recent data have clearly shown that a sustained virologic response can be achieved in different HCV infected patient populations with various interferon-free treatment regimens. Despite the successful implementation of telaprevir- and boceprevir-based triple therapies, all-oral regimens will certainly become a first choice for a number of HCV-infected patients in the very near future, as triple therapy approaches are burdened with significant side-effects and limited success in patients with advanced liver fibrosis and prior null-response to pegylated interferon-α (pegIFN-α)/ribavirin therapy. However, available data from phase I and II clinical trials evaluating interferon-free regimens have not yet revealed a clearly outstanding all-oral combination, and numerous challenges remain to be addressed by intensive ongoing and future research. In particular, thus far evaluated all-oral regimens did not cure a satisfactory percentage of patients with unfavorable baseline characteristics, namely patients infected with HCV genotype 1a, previous null-response to pegIFN-α/ribavirin, or liver cirrhosis. In this review, we summarize available data of interferon-free regimens for the treatment of chronic hepatitis C and assess implications for perspectives and challenges in the further development of all-oral therapies.
Verfasserangaben: | Christian LangeGND, Stefan ZeuzemORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-768717 |
DOI: | https://doi.org/10.1016/j.jhep.2012.10.019 |
ISSN: | 0168-8278 |
Titel des übergeordneten Werkes (Englisch): | Journal of Hepatology |
Verlag: | Elsevier |
Verlagsort: | Amsterdam |
Dokumentart: | Wissenschaftlicher Artikel |
Sprache: | Englisch |
Datum der Veröffentlichung (online): | 24.10.2012 |
Datum der Erstveröffentlichung: | 24.10.2012 |
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Datum der Freischaltung: | 12.10.2023 |
Freies Schlagwort / Tag: | All-oral therapy; Antiviral therapy; Directly acting antiviral agent; Hepatitis C virus; Null responder |
Jahrgang: | 58.2013 |
Ausgabe / Heft: | 3 |
Seitenzahl: | 10 |
Erste Seite: | 583 |
Letzte Seite: | 592 |
HeBIS-PPN: | 516557343 |
Institute: | Medizin |
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Lizenz (Deutsch): | Creative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International |